Exploring New Frontiers in Hepatocellular Carcinoma Treatment: Insights from the CheckMate 9DW Trial

In our latest “Ask the Author” session, Professor Peter Galle presented the groundbreaking results of the CheckMate 9DW clinical trial, which explored the efficacy of the combination of nivolumab and ipilimumab versus lenvatinib or sorafenib as first-line treatments for unresectable hepatocellular carcinoma (HCC). Below you will find the video as well as the summary: Background:

Read more >

Enter your email address to stay in touch with the Foundation